A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS
Completed
Pharmacia
Phase 4
1969-12-31
To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring serum
rifabutin levels and adjusting the dose accordingly. To combine rifabutin with ethambutol to
examine the effect of combination therapy in preventing or delaying the incidence of MAC
bacteremia in this patient population.
Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease
Completed
Abbott
Phase 4
1995-08-01
To determine the safety and tolerance of clarithromycin given three times per week in
combination with multiple drugs including rifabutin three times per week
Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease
Completed
Pfizer
Phase 4
1995-08-01
To determine the safety and tolerance of clarithromycin given three times per week in
combination with multiple drugs including rifabutin three times per week
Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease
Completed
The University of Texas Health Science Center at Tyler
Phase 4
1995-08-01
To determine the safety and tolerance of clarithromycin given three times per week in
combination with multiple drugs including rifabutin three times per week
Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
Completed
Pfizer
Phase 4
1994-12-01
To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three
times weekly in the treatment of lung infection with M. avium complex(MAC)
Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
Completed
The University of Texas Health Science Center at Tyler
Phase 4
1994-12-01
To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three
times weekly in the treatment of lung infection with M. avium complex(MAC)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
